Search Results - "Ohkura, Masayuki"

Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial by Chuah, Charles, Koh, Liang Piu, Numbenjapon, Tontanai, Zang, Dae Young, Ong, Kiat Hoe, Do, Young Rok, Ohkura, Masayuki, Ono, Chiho, Viqueira, Andrea, Cortes, Jorge E., Brümmendorf, Tim H.

“…Bosutinib is approved in the United States, Europe, Japan, and other countries for treatment of newly diagnosed chronic phase (CP) chronic myeloid leukemia…”
Get full text

Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia by Hino, Masayuki, Matsumura, Itaru, Fujisawa, Shin, Ishizawa, Kenichi, Ono, Takaaki, Sakaida, Emiko, Sekiguchi, Naohiro, Tanetsugu, Yusuke, Fukuhara, Kei, Ohkura, Masayuki, Koide, Yuichiro, Takahashi, Naoto

“…This open-label, single-arm, phase 2 study (ClinicalTrials.gov, NCT03128411) evaluated the efficacy, safety, and pharmacokinetics of bosutinib at a starting…”
Get full text

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study by Seto, Takashi, Hayashi, Hidetoshi, Satouchi, Miyako, Goto, Yasushi, Niho, Seiji, Nogami, Naoyuki, Hida, Toyoaki, Takahashi, Toshiaki, Sakakibara‐Konishi, Jun, Morise, Masahiro, Nagasawa, Takashi, Suzuki, Mie, Ohkura, Masayuki, Fukuhara, Kei, Thurm, Holger, Peltz, Gerson, Nishio, Makoto

“…Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is…”
Get full text

Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis by Takahashi, Naoto, Cortes, Jorge E., Sakaida, Emiko, Ishizawa, Kenichi, Ono, Takaaki, Doki, Noriko, Matsumura, Itaru, García-Gutiérrez, Valentín, Rosti, Gianantonio, Ono, Chiho, Ohkura, Masayuki, Tanetsugu, Yusuke, Viqueira, Andrea, Brümmendorf, Tim H.

“…Bosutinib has been investigated in multiple clinical trials globally, including Japan, for treatment of chronic myeloid leukemia (CML). A pooled analysis of…”
Get full text

Efficacy of Varenicline for Cigarette Reduction Before Quitting in Japanese Smokers: A Subpopulation Analysis of the Reduce to Quit Trial by Nakamura, Masakazu, MD, Abe, Masaaki, PhD, Ohkura, Masayuki, PhD, Treadow, Joan, RN, BSN, Yu, Ching-Ray, PhD, Park, Peter W., PhD

“…Abstract Purpose This prospective analysis of the Japanese subpopulation of the varenicline reduce to quit study was conducted to evaluate whether results for…”
Get full text

Predictors of Lapse and Relapse to Smoking in Successful Quitters in a Varenicline Post Hoc Analysis in Japanese Smokers by Nakamura, Masakazu, MD, Oshima, Akira, MD, Ohkura, Masayuki, PhD, Arteaga, Carmen, PhD, Suwa, Kiyomi, BA

“…Abstract Background The efficacy of the smoking-cessation agent varenicline has been reported in Asian smokers; however, few studies have investigated factors…”
Get full text

Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer–related bone metastases by Yonemori, Kan, Fujiwara, Yasuhiro, Minami, Hironobu, Kitagawa, Koichi, Fujii, Hirofumi, Arai, Tatsuhiro, Sohn, Winnie, Ohkura, Masayuki, Ohtsu, Tomoko

“…Denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor–kappa B ligand (RANKL), suppresses bone resorption. This open‐label,…”
Get full text

Efficacy and Safety of Additional 200-mg Dose of Celecoxib in Adult Patients With Postoperative Pain Following Extraction of Impacted Third Mandibular Molar: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Japan by Saito, Ken‘ichi, DDS, PhD, Kaneko, Akihiro, DDS, PhD, Machii, Katsuyuki, MD, PhD, Ohta, Hiroyoshi, MS, Ohkura, Masayuki, PhD, Suzuki, Makoto, PhD

“…Abstract Background Although third mandibular molar extraction is a widely used and validated model of acute pain for evaluating analgesic efficacy, a large…”
Get full text

Pharmacodynamics and Pharmacokinetics of AMG 531, a Thrombopoiesis-Stimulating Peptibody, in Healthy Japanese Subjects: A Randomized, Placebo-Controlled Study by Kumagai, Yuji, Fujita, Tomoe, Ozaki, Machiko, Sahashi, Kunihiko, Ohkura, Masayuki, Ohtsu, Tomoko, Arai, Yoshihiro, Sonehara, Yusuke, Nichol, Janet L.

“…AMG 531 is a novel thrombopoiesis‐stimulating peptibody being investigated for the treatment of chronic immune thrombocytopenic purpura. This double‐blind,…”
Get full text

An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia by Ohta, Hiroyoshi, Oka, Hiroshi, Usui, Chie, Ohkura, Masayuki, Suzuki, Makoto, Nishioka, Kusuki

“…Abstract Objectives To assess the long-term safety and efficacy of pregabalin for the treatment of Japanese patients with fibromyalgia (FM). Methods This…”
Get full text

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors by Doi, Toshihiko, Ohtsu, Atsushi, Tahara, Makoto, Tamura, Tomohide, Shirao, Kuniaki, Yamada, Yasuhide, Otani, Satoru, Yang, Bing-Bing, Ohkura, Masayuki, Ohtsu, Tomoko

“…Background Panitumumab is a fully human, monoclonal antibody against the epidermal growth factor receptor. Previous studies in non-Japanese patients with solid…”
Get full text

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia by Takahashi, Naoto, Matsumura, Itaru, Fujisawa, Shin, Ishizawa, Kenichi, ONO, Takaaki, Sakaida, Emiko, Sekiguchi, Naohiro, Tanetsugu, Yusuke, Fukuhara, Kei, Ohkura, Masayuki, Koide, Yuichiro, Hino, Masayuki

“…Background: Bosutinib, a Src/Abl tyrosine kinase inhibitor, is approved at a starting dose of 500 mg once daily (QD) in many countries, including Japan, for…”
Get full text

A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia by Ohta, Hiroyoshi, Oka, Hiroshi, Usui, Chie, Ohkura, Masayuki, Suzuki, Makoto, Nishioka, Kusuki

“…Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness. Prior trials have demonstrated the efficacy of pregabalin for the relief of…”
Get full text

PF-05212384 + irinotecan Phase II study in metastatic colorectal cancer (mCRC): B2151005 Japanese lead-in-cohort (J-LIC) by Yoshino, Takayuki, Shitara, Kohei, Taniguchi, Hiroya, Brega, Nicoletta, Ohkura, Masayuki, Ono, Chiho, Suzuki, Mie, Vermette, Jennifer, Muro, Kei

Get full text

An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia by Ohta, Hiroyoshi, Oka, Hiroshi, Usui, Chie, Ohkura, Masayuki, Suzuki, Makoto, Nishioka, Kusuki

“…Objectives To assess the long-term safety and efficacy of pregabalin for the treatment of Japanese patients with fibromyalgia (FM). Methods This 53-week,…”
Get full text

A Phase 2 Open-Label, Sequential-Cohort, Dose-Escalation Study of AMG 531 in Japanese Patients with Chronic Immune Thrombocytopenic Purpura (ITP) by Shirasugi, Yukari, Ando, Kiyoshi, Hashino, Satoshi, Nagasawa, Toshiro, Kurata, Yoshiyuki, Kishimoto, Yuji, Iwato, Koji, Sonehara, Yusuke, Ohkura, Masayuki, Ohtsu, Tomoko, Nichol, Janet L.

“…AMG 531 is a novel thrombopoiesis-stimulating peptibody that is being studied for its ability to increase platelet production by stimulating the thrombopoietin…”
Get full text

Platelet Aggregation Analysis of AMG 531 in a Randomized, Placebo-Controlled Study in Healthy Japanese Subjects by Kumagai, Yuji, Fujita, Tomoe, Ozaki, Machiko, Sahashi, Kunihiko, Ohkura, Masayuki, Ohtsu, Tomoko, Arai, Yoshihiro, Sonehara, Yusuke, Nichol, Janet

“…AMG 531 is a novel thrombopoiesis-stimulating peptibody currently being investigated for the treatment of chronic immune thrombocytopenic purpura. This study…”
Get full text

p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy by Sunada, Fumiko, Itabashi, Masayuki, Ohkura, Hisanao, Okumura, Toshiyuki

“…AIM： Esophageal squamous cell carcinoma is generally sensitive to chemoradiotherapy （CRT）, but some cases are not. Using a retrospective analysis, we aimed to…”
Get full text